digital therapeutics

Advancements in Digital Therapeutics: An Overview of the Latest Clinical Trials

This blog post provides an overview of the latest advancements in digital therapeutics, focusing on key clinical trials and the role of Contract Research Organizations (CROs) in facilitating their execution...
digital therapeutics

Boehringer Ingelheim, Click Therapeutics expand their collaboration to develop digital therapeutics for schizophrenia

The partnership aims to provide additional treatment options to those living with schizophrenia, where there remains a significant unmet need...
digital therapeutics

Research: Digital therapeutics users in the US to grow from from 7M in 2022...

This growth will be driven by the increasing prevalence of diabetes, allied with initiatives to expand digital therapeutics coverage and cost reimbursement.
reSET digital therapeutic

Pear Therapeutics to offer its digital therapeutics through telehealth partners

The company's first telehealth offering is with PursueCare to offer patients an end-to-end virtual continuum of comprehensive addiction recovery care.
Pear Therapeutics homepage

Pear Therapeutics ended 2021 with $4.2M in revenue, expects $22M this year

Yes, the digital therapeutics market is taking off...
Akili EndeavorRx study

Study: Akili’s EndeavorRx digital therapeutic works

Data from the study show that EndeavorRx treatment resulted in increased brain activity related to attention function, as measured by EEG.
Alex Therapeutics

Pfizer, Alex Therapeutics team-up to provide evidence-based digital therapeutics starting with Germany

The partnership will utilize Alex Therapeutics' digital therapeutics platform, which combines evidence-based psychology, primarily CBT and ACT with AI.
Ensemble by Happify Health

Happify unveils the first digital therapeutics to treat both MDD and GAD

Designed as an adjunct to care for MDD and GAD, Ensemble must be prescribed by a clinician to treat these disorders.
Pear Therapeutics homepage

Digital therapeutics company Pear Therapeutics to go public in a $1.6B SPAC deal

The deal provides additional investment to capitalize on Pear's position by investing in the commercialization of its three FDA-authorized products.
MindMaze Living Room Stills

MindMaze scores new partners, enters new markets

Bringing the future of brain repair for stroke, Parkinson's, and other neurological conditions to patients in Latin America, Europe and Middle East.